מבירט ישראל - עברית - Ministry of Health

מבירט

abbvie biopharmaceuticals ltd, israel - glecaprevir; pibrentasvir - טבליות מצופות פילם - pibrentasvir 40 mg; glecaprevir 100 mg - glecaprevir and pibrentasvir

מבירט ישראל - עברית - Ministry of Health

מבירט

abbvie biopharmaceuticals ltd, israel - glecaprevir; pibrentasvir - טבליות מצופות פילם - pibrentasvir 40 mg; glecaprevir 100 mg - glecaprevir and pibrentasvir

קלטרה תמיסה ישראל - עברית - Ministry of Health

קלטרה תמיסה

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir

קלטרה תמיסה ישראל - עברית - Ministry of Health

קלטרה תמיסה

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir

רקורמון IU 5000 ישראל - עברית - Ministry of Health

רקורמון iu 5000

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

רקורמון 10000 IU ישראל - עברית - Ministry of Health

רקורמון 10000 iu

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 10000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with chemotherapy. treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * deficiency is defined as an

רקורמון 4000 IU ישראל - עברית - Ministry of Health

רקורמון 4000 iu

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 4000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

רקורמון 6000 יחבל ישראל - עברית - Ministry of Health

רקורמון 6000 יחבל

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 6000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

רקורמון 30000 IU ישראל - עברית - Ministry of Health

רקורמון 30000 iu

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 30000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with chemotherapy . treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency and are receiving anti-tumor therapy. deficiency is defined as an i

זומקטון 10 מג ישראל - עברית - Ministry of Health

זומקטון 10 מג

ferring pharmaceuticals ltd - somatropin - אבקה וממס להכנת תמיסה להזרקה - somatropin 10 mg - somatropin - somatropin - short stature due to pituitary growth hormone deficiency turner's syndrome, children suffering from renal insufficiency. children : short stature due to inadequate or failed secretion of pituitary growth hormone or turner's syndrome. short stature in children with renal insufficiency.